PT-141 (Bremelanotide) side effects and safety context

PT-141's most common side effect is nausea, which affected 40% of women in clinical trials (versus 1.3% on placebo) — striking enough that 13% needed anti-nausea medication and 8% quit treatment over it (Vyleesi label, DailyMed). Behind nausea come flushing, injection-site reactions, and headache, plus two effects that shape the label's hard limits: a transient blood-pressure rise and cumulative skin darkening.

Because bremelanotide completed full drug approval, these are measured frequencies from controlled trials — a level of quantification almost no other compound sold as a "research peptide" can offer. The same numbers apply, at best, to gray-market PT-141; an unverified vial can only add risks, never subtract them.

Adverse reactions reported in ≥2% of Vyleesi-treated patients in the phase 3 trials (label):

• Nausea — 40% (placebo 1.3%); typically worst with the first dose and improving by the second; pre-treating with ondansetron did not help.
• Flushing — 20.3%
• Injection-site reactions — 13.2%
• Headache — 11.3%
• Vomiting — 4.8%

The 52-week open-label extension of the RECONNECT trials found the same pattern with no new safety signals — nausea 40.4%, flushing 20.6%, headache 12.0% — and nausea was the only severe adverse event reported by more than one participant (Simon et al., Obstet Gynecol 2019). In the placebo-controlled phase, most events were mild or moderate (Kingsberg et al. 2019).

Each dose transiently raises blood pressure — up to about 6 mmHg systolic and 3 mmHg diastolic, peaking 2–4 hours post-dose — while heart rate falls by up to 5 beats per minute, with both typically resolving within 12 hours (label). A dedicated ambulatory monitoring study of the approved 1.75 mg dose measured systolic increases of about 3 mmHg across the first four hours, with individual peaks lasting under 15 minutes (White et al., J Hypertens 2017).

Small and brief — in screened, healthy trial participants. That qualifier is the point: this same blood-pressure effect derailed bremelanotide's earlier intranasal erectile-dysfunction program, where absorption was erratic and exposures spiked unpredictably (White et al. 2017). It is also why the label limits dosing to once per 24 hours and contraindicates the drug outright in uncontrolled hypertension and known cardiovascular disease.

Bremelanotide activates MC1R — the pigmentation receptor its parent compound melanotan-II targets deliberately for tanning. The result: focal hyperpigmentation of the face, gums, or breasts in 1% of women using up to 8 doses per month, but in 38% of participants after just 8 days of daily dosing in a separate study (label). Darkening did not fully resolve in everyone after stopping, and people with darker skin are at higher risk.

The frequency-dependence is the practical lesson: the approved use pattern keeps this effect rare, while the "more is better" logic common in gray-market use pushes directly toward the 38% scenario — potentially permanently.

• Uncontrolled hypertension or known cardiovascular disease — contraindicated, per the blood-pressure effect above.

• Oral naltrexone — bremelanotide can significantly decrease naltrexone's systemic exposure; the label says to avoid the combination in people taking naltrexone for alcohol or opioid use disorder, where lost efficacy has real consequences (label).

• Slowed gastric emptying — bremelanotide can delay absorption of some oral medicines taken around the same time; a prescriber evaluates what else is on board.

For a broader look at who tends to be cautioned away from peptide compounds generally, see who should avoid using peptides.

Everything quantified above was measured with the pharmaceutical product: a fixed 1.75 mg autoinjector, sterile and dose-verified, in screened participants. Research-grade PT-141 powder adds unknowns on top — identity, purity, sterility, and the actual milligrams delivered after hand-reconstitution — and removes the screening (blood pressure checks, interaction review) that the trial population had. The side-effect list stays; the safeguards don't. Context on the main page: PT-141 (bremelanotide).